Genovis Q2 2023: Continued strong growth trajectory in analytics - Redeye

Redeye remains positive on Genovis following a Q2 that showcased 40% sales growth in the analytics business, alongside EBIT margins of 20%. The bioprocess order we expected in Q2 did not materialize, we will reconsider our forecasting approach to accomodate for the uncertainty and difficulty of timing these orders.

Länk till analysen i sin helhet: https://www.redeye.se/research/937803/genovis-q2-2023-continued-strong-growth-trajectory-in-analytics?utm_source=finwire&utm_medium=RSS